EP Patent

EP1921916A2 — Genistein inhibition of transthyretin amyloidosis

Assigned to Scripps Research Institute · Expires 2008-05-21 · 18y expired

What this patent protects

Genistein is an excellent transthyretin amyloidogenesis inhibitor and exhibits excellent binding selectivity in plasma. Treatment of patients having transthyretin amyloidosis with therapeutic agents containing genistein is disclosed to ameliorate the disease condition.

USPTO Abstract

Genistein is an excellent transthyretin amyloidogenesis inhibitor and exhibits excellent binding selectivity in plasma. Treatment of patients having transthyretin amyloidosis with therapeutic agents containing genistein is disclosed to ameliorate the disease condition.

Drugs covered by this patent

Patent Metadata

Patent number
EP1921916A2
Jurisdiction
EP
Classification
—
Expires
2008-05-21
Drug substance claim
No
Drug product claim
No
Assignee
Scripps Research Institute
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.